Table 3.
Endothelial function at baseline and after 12 wk of placebo or Endocalyx Pro
| Variable | Placebo (n = 11) |
Endocalyx Pro (n = 12) |
Between-Group Comparison |
|||
|---|---|---|---|---|---|---|
| Baseline | 12-wk | Baseline | 12-wk | B (95% CI) | Between-Group P Value | |
| FMD, % | 3.7 (2.8,5.2) | 3.5 (2.7,6.0) | 3.4 (2.9,6.2) | 5.3 (4.3,6.8) | 1.16 (0.77,1.74)b | 0.48 |
| FMD, mm | 0.14 (0.11,0.18) | 0.13 (0.11,0.20) | 0.16 (0.09,0.22) | 0.18 (0.14,0.26) | 1.16 (0.79,1.70)b | 0.46 |
| Baseline diameter, mm | 4.05 ± 0.72 | 4.10 ± 0.70 | 3.64 ± 0.73 | 3.68 ± 0.75 | −0.02 (−0.20,0.16)a | 0.81 |
| Time to peak, s | 35.3 ± 27.7 | 42.1 ± 22.6 | 55.2 ± 25.8 | 56.3 ± 20.7 | −3.8 (−35,24)a | 0.70 |
| SRAUC, 1/s | 17,184 ± 12,071 | 20,751 ± 8,910 | 42,339 ± 20,449 | 37,484 ± 12,967 | −8,062 (−23,819, 7,695)a | 0.30 |
| Peak FMD:SRAUC, a.u. | 0.29 (0.16,0.63) | 0.21 (0.13,0.41)* | 0.10 (0.07,0.16) | 0.18 (0.12,0.20) | 2.41 (1.41,4.13)b | 0.001* |
| BFAUC, a.u. | 13,132 (9,480, 14,505) | 14,407 (11,493, 16,213) | 15,595 (12,465, 18,273) | 18,493 (12,179, 20,202) | 0.95 (0.79,1.14)b | 0.55 |
A linear mixed-effects model was used for variables denoted means ± SD and a Gamma mixed-effects model was used for variables denoted with median (interquartile range). SRAUC and peak FMD:SRAUC were calculated in n = 10 participants in both the Endocalyx Pro groups. BFAUC was calculated in n = 10 participants in the placebo group and n = 11 participants in the Endocalyx Pro group. BF, blood flow; CI, confidence interval; FMD, flow-mediated dilation; SR, shear rate.
*
P < 0.05.
a
Normally distributed variables are shown as the mean difference.
b
Nonnormally distributed variables are shown as the mean ratio.